Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CPGJ-602
i
Other names:
CPGJ-602, CPGJ602, CPGJ 602, 602
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3)
News
Trials
Company:
3SBio
Drug class:
EGFR antagonist
Related drugs:
‹
CKD-702 (6)
SCT200 (4)
rezivertinib (2)
MCLA-158 (2)
cetuximab biosimilar (CDP-1) (0)
BTG-002814 (0)
KL 140 (cetuximab biosimilar) (0)
CKD-702 (6)
SCT200 (4)
rezivertinib (2)
MCLA-158 (2)
cetuximab biosimilar (CDP-1) (0)
BTG-002814 (0)
KL 140 (cetuximab biosimilar) (0)
›
Associations
(3)
News
Trials
VERI cancer hierarchy
Reset Filters
NRAS wild-type
Colorectal Cancer
NRAS wild-type
Colorectal Cancer
CPGJ-602
Sensitive: C2 – Inclusion Criteria
CPGJ-602
Sensitive
:
C2
CPGJ-602
Sensitive: C2 – Inclusion Criteria
CPGJ-602
Sensitive
:
C2
BRAF wild-type
Colorectal Cancer
BRAF wild-type
Colorectal Cancer
CPGJ-602
Sensitive: C2 – Inclusion Criteria
CPGJ-602
Sensitive
:
C2
CPGJ-602
Sensitive: C2 – Inclusion Criteria
CPGJ-602
Sensitive
:
C2
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
CPGJ-602
Sensitive: C2 – Inclusion Criteria
CPGJ-602
Sensitive
:
C2
CPGJ-602
Sensitive: C2 – Inclusion Criteria
CPGJ-602
Sensitive
:
C2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.